ClinicalTrials.Veeva

Menu

Insulin and Sarcopenia in the Elderly

The University of Texas System (UT) logo

The University of Texas System (UT)

Status and phase

Completed
Phase 1

Conditions

Sarcopenia

Treatments

Drug: Insulin Regular
Drug: Sodium Nitroprusside
Other: mixed meal
Drug: L-NMMA

Study type

Interventional

Funder types

Other
NIH

Identifiers

NCT00690534
05-090
5R01AG018311 (U.S. NIH Grant/Contract)

Details and patient eligibility

About

Muscle loss with aging is a significant contributor to disability in older people. Our general hypothesis is that loss of muscle with aging, known as sarcopenia, may be due to inability of muscle to grow in response to insulin. Our goal is to determine the mechanisms underlying this age-related insulin resistance of muscle proteins, which will allow us to define in the future specific interventions to target this defect and provide the scientific basis for the prevention and treatment of sarcopenia.

Full description

Our general hypothesis is that a reduced response of muscle protein anabolism to insulin plays an important role in the loss of muscle mass with aging. Our goal is to determine the mechanisms underlying the age-related insulin resistance of muscle proteins, which will allow us to define specific interventions to target this defect and provide the scientific basis for the prevention and treatment of sarcopenia.

Our previous studies indicate that the response of muscle proteins to the anabolic action of insulin is impaired in healthy older adults as compared to younger controls, which hampers the anabolic effect of mixed feeding on muscle proteins. These changes are associated with an age-related reduction in the vasodilatory response to insulin, which, from our data, appears to be a potentially important mediator of the physiological anabolic effect of insulin on muscle proteins. Preliminary data from our laboratory also suggest that in older subjects a single bout of aerobic exercise may restore the normal response of blood flow, muscle protein synthesis and anabolism to insulin.

Therefore, we will test in healthy subjects the following specific hypotheses:

  1. Insulin-induced increases in blood flow and muscle perfusion are necessary for the physiological stimulation of muscle protein synthesis and anabolism by insulin.
  2. Aging reduces the vascular sensitivity to insulin, which prevents the physiological increase in blood flow and muscle perfusion in response to insulin, thereby decreasing the response of muscle protein synthesis and net balance to the anabolic action of insulin and mixed feeding.
  3. Aerobic exercise can restore, in older subjects, the insulin-induced increase in blood flow and muscle perfusion to youthful levels, thus normalizing the anabolic effect of insulin and mixed feeding on muscle protein synthesis and net muscle protein balance.

We will use state-of the art stable isotope tracer techniques to measure muscle protein turnover, and a newly developed method to measure muscle perfusion in young and older subjects. The results of these studies will allow us to better define the physiological mechanisms of action of insulin on muscle protein anabolism, advance our knowledge on the pathophysiology of sarcopenia, and provide the scientific basis for the behavioral and/or pharmacological treatment of muscle loss with aging.

Enrollment

88 patients

Sex

All

Ages

18 to 85 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  1. Age 18-40 yrs, and 65-85 yrs.
  2. Ability to sign consent form (score >23 on the 30-item Mini Mental State Examination, MMSE)
  3. Stable body weight for at least 3 months

Exclusion criteria

  1. Physical dependence or frailty (impairment in any of the Activities of Daily Living (ADL), history of falls (>2/year) or significant weight loss in the past year)
  2. Exercise training (>2 weekly sessions of moderate to high intensity aerobic or resistance exercise)
  3. Pregnancy or nursing women.
  4. Significant heart, liver, kidney, blood or respiratory disease
  5. Peripheral vascular disease
  6. Diabetes mellitus or other untreated endocrine disease
  7. Active cancer
  8. Recent (within 6 months) treatment with anabolic steroids, or corticosteroids.
  9. Alcohol or drug abuse
  10. Severe depression (>5 on the 15-item Geriatric Depression Scale, GDS)
  11. Potential subjects who have recently donated blood in the past 60 days will be excluded from participating in the study.

Trial design

Primary purpose

Basic Science

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

88 participants in 11 patient groups

CMAY
Active Comparator group
Description:
Insulin in young
Treatment:
Drug: Insulin Regular
IMAY
Experimental group
Description:
L-NMMA + insulin in young
Treatment:
Drug: L-NMMA
Drug: Insulin Regular
SNPY
Experimental group
Description:
SNP in young
Treatment:
Drug: Sodium Nitroprusside
CSNP
Active Comparator group
Description:
Insulin in elderly
Treatment:
Drug: Insulin Regular
ISNP
Experimental group
Description:
SNP in elderly
Treatment:
Drug: Insulin Regular
Drug: Sodium Nitroprusside
SNPE
Experimental group
Description:
SNP in elderly
Treatment:
Drug: Sodium Nitroprusside
CMealO
Active Comparator group
Description:
Meal in elderly
Treatment:
Other: mixed meal
SMealO
Experimental group
Description:
SNP+meal in elderly
Treatment:
Other: mixed meal
Drug: Sodium Nitroprusside
MealY
Active Comparator group
Description:
meal in young
Treatment:
Other: mixed meal
ExIns
Experimental group
Description:
insulin+exercise in elderly
Treatment:
Drug: Insulin Regular
ExMeal
Experimental group
Description:
meal+exercise in elderly
Treatment:
Other: mixed meal

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems